CRISPR Therap

Q2 FY2026 EarningsCRSP Q2 FY26 exceeded consensus on both top and bottom lines: revenue was $10.18M vs. $7.43M expected, while Diluted EPS loss of $0.94 beat the estimated $1.17 loss. The top-line beat was driven by a $10.0M collaboration revenue milestone, while CASGEVY generated $76M in total sales (40% shared profit model) showing strong 78% QoQ momentum. A significant reduction in operating expenses, particularly R&D and acquired IPR&D compared to the prior year, contributed to the narrowed net loss.